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PDxMD Cardiology
Editorial Board; Philadelphia; 2003; Elsevier Science; 651
pages; $49.95.
This book is part of the PDxMD Medical Condition Series, a
new, evidence-based clinical information system that is continu-
ously updated by expert contributors. This book represents the
print version of the comprehensive approach offered online. There
are 29 chapters, each on a specific topic. The many chapters of
interest to vascular specialists include subjects such as angina,
abdominal aortic aneurysm, aortic dissection, deep venous throm-
bosis, hyperlipidemia, hypertension, myocardial infarction, periph-
eral vascular disease, Raynaud phenomenon, superior vena cava
syndrome, thrombophlebitis, and varicose veins.
Each condition is outlined in an exhaustive manner, beginning
with ICD-9-CM (International Classification of Doseases, ninth
revision, Clinical modification) code and progressing through
synonyms, cardinal features, causes, rare causes, contributory or
predisposing factors, epidemiology, differential diagnosis, signs
and symptoms, associated disorders, consider consult, investiga-
tion of the patient, diagnostic decision, clinical pearls, tests, treat-
ment, summary of therapeutic options, follow-up, drugs and other
therapies, outcomes, prevention, and a list of resources.
The authors provide a description of their criteria for evi-
dence-based medicine. They evaluate all cited evidence according
to the American Academy of Family Practice Recommended Basic
Model for Evaluating and Categorizing the Clinical Content of
Continuing Medical Education, based on the model used by the
University of Michigan: level M, evidence from either meta-anal-
ysis or multiple randomized controlled trials; level P, a well-
designed prospective clinical trial or several prospective clinical
cohort studies with consistent findings, without randomization;
and level S, evidence from epidemiologic or physiologic studies.
Along with the print version, there is access to the online
version, with more than 1400 differential diagnoses to search,
information on 450 medical conditions and more than 750 drugs
and other therapies, and 300 patient topic information sheets that
can be customized and given to patients.
This is an interesting approach to help all involved in patient
care. The authors have done a lot of work to organize a thorough
outline of evaluation, diagnosis, and treatment and to provide
literature documentation for treatment. This book will be of special
interest to medical students, house staff, and young clinicians.
James O. Menzoı´an, MD
Boston Medical Center
Boston, Mass
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The new angiotherapy
Tai-Ping D. Fan, Elise C. Kohn; Totowa, NJ; 2002; Humana
Press; 609 pages; $150.00.
During the past decade there has been an explosion of interest
in angiogenesis at the level of both laboratory research and clinical
investigation. Classically defined, angiogenesis is the sprouting of
new blood vessels from preexisting vessels, whereas vasculogenesis
is de novo formation of such vessels during embryogenesis. As
several of the contributors in this text point out, such mutually
exclusionary categorization is oversimplification, with the proba-
bility that vasculogenesis may also occur later, in adulthood. Both
of these processes are dynamic and complex, with positive and
negative modulators, which have been likened to a multidimen-
sional coagulation cascade. Vasculogenesis and angiogenesis are
involved in a multitude of disease states, ranging from arterio-
venous malformation, hemangioma, atherosclerosis, venous and
arterial ulceration, and scleroderma, to diabetic retinopathy, rheu-
matoid arthritis, wound healing, and neoplasms. We are just be-
ginning to gain a rudimentary understanding of angiogenesis, and
its mechanisms and regulation. Angiotherapy, broadly defined, is
the targeting of blood vessels for intervention, during differentia-
tion, maintenance, or homeostasis, in either normal or disease
processes. A textbook on this topic is timely and provides a useful
summary of present knowledge.
The New Angiotherapy is written by an international group of
experts in the field of angiogenesis, with many contributors who
are colleagues of the two editors at the University of Cambridge
and the National Institutes of Health. Each chapter is clearly
written, succinct, and extensively referenced. The first chapter
clarifies the distinction and relationship between vasculogenesis
and angiogenesis. The subsequent half dozen chapters describe
and explain our current understanding of the molecular and cellu-
lar biology of angiogenesis as derived from previous and recent in vitro
and in vivo studies. These are followed by descriptions of the various
components of angiogenesis, including the angiopoietins, extracellu-
lar matrix proteins, vascular endothelial growth factor, fibroblast
growth factor, and other cytokines and vasoactive peptides.
Following these descriptions of the basic science of angiogenesis,
8 chapters effectively connect the basic pathophysiologic features with
a variety of clinical diseases. These chapters educate the reader about
the pathogenesis of these disease processes, including wound healing
and repair, rheumatoid arthritis, neoplasms and metastases, and cor-
onary and peripheral arterial occlusive diseases, and highlight the
mechanistic associations with angiogenesis. Each of these chapters
also contains a thorough literature review of relevant preclinical and
clinical studies for therapeutic angiogenesis in these disease states. The
last chapter in this section, “Contact-guided angiogenesis and tissue
engineering,” describes the emerging therapeutic concept of tissue-
engineered blood vessels from cultured endothelial cells, tagging
them with growth factors, and implanting them in vivo to stimulate
angiogenesis.
If there is angiogenesis, there is also anti-angiogenesis. The
book devotes ane entire section to anti-angiogenesis and expounds
on possible anti-angiogenic targets. Of interest is Chapter 19,
which gives an overview of some of these modulators, including
cyclosporin A, antimicrobial agents, and steroids that have angio-
static effects. Possible targets discussed at length are the tyrosine
kinase receptors, endothelial monocyte-activating polypeptide II,
and CD105. There are also 2 excellent chapters that review the
possible methods of gene therapy for therapeutic anti-angiogenesis
and vascular targeting with monoclonal antibodies.
The last section of the book identifies the vast potential for
clinical application of angiogenesis and anti-angiogenesis, and
defines some of the cutting-edge strategies that may be used in
these processes. Several helpful tables list key clinical published
studies. One chapter describes in depth the newest members of the
anti-angiogenesis family, angiostatin and endostatin, which are
endogenous molecules that may have substantial future therapeu-
tic applicability. These chapters also provide recommendations for
conducting appropriate clinical trials in angiotherapy.
Overall, this is a well-written, concise, and evidence-based
textbook that deals with both the facts and concepts of angiogen-
esis and possibilities for future angiotherapy. I recommend it in
particular to academic physicians and investigators in vascular
surgery, cardiovascular medicine and surgery, oncology, dermatol-
ogy, and rheumatology.
John Blebea, MD
Hershey, Pa
doi:10.1067/mva.2003.301
1136 JOURNAL OF VASCULAR SURGERY/May 2003
